Identification

Name
Ofloxacin
Accession Number
DB01165  (APRD00502)
Type
Small Molecule
Groups
Approved
Description

A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Structure
Thumb
Synonyms
  • 8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
  • Ofloxacine
  • Ofloxacino
  • Ofloxacinum
  • OFLX
External IDs
DL-8280 / HOE 280 / HOE-280
Product Ingredients
IngredientUNIICASInChI Key
Ofloxacin hydrochlorideI2UWV315WA118120-51-7CAOOISJXWZMLBN-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Floxin I.V. Liq 20mg/mlLiquid20 mgIntravenousOrtho Pharmaceutical, Division Of Janssen Ortho Inc.Not applicableNot applicableCanada
Floxin Tablets 200mgTablet200 mgOralJanssen Pharmaceuticals1992-12-312002-07-31Canada
Floxin Tablets 300mgTablet300 mgOralJanssen Pharmaceuticals1990-12-312006-12-21Canada
Floxin Tablets 400mgTablet400 mgOralJanssen Pharmaceuticals1990-12-312007-01-10Canada
OcufloxSolution0.3 %OphthalmicAllergan1995-12-31Not applicableCanada
OcufloxSolution / drops3 mg/mLOphthalmicAllergan1993-08-01Not applicableUs
Ofloxacin TabletsTablet200 mgOralAa Pharma Inc1998-02-042016-08-02Canada
Ofloxacin TabletsTablet400 mgOralAa Pharma Inc1998-02-172016-08-02Canada
Ofloxacin TabletsTablet300 mgOralAa Pharma Inc1998-02-042016-08-02Canada
Sandoz OfloxacinSolution0.3 %OphthalmicSandoz Canada Incorporated2012-07-24Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ofloxacinSolution0.3 %OphthalmicApotex Corporation2004-01-22Not applicableCanada
Floxin OticSolution / drops3 mg/mLAuricular (otic)ALMATICA PHARMA INC.2016-07-252017-02-14Us
Novo-ofloxacinTablet400 mgOralNovopharm Limited2004-06-112012-05-08Canada
Novo-ofloxacinTablet300 mgOralNovopharm Limited2004-06-112012-05-08Canada
Novo-ofloxacinTablet200 mgOralNovopharm Limited2004-06-112012-05-08Canada
OfloxacinSolution / drops3 mg/mLOphthalmicRpk Pharmaceuticals, Inc.2008-07-01Not applicableUs
OfloxacinSolution / drops3 mg/mLOphthalmicPreferreed Pharmaceuticals Inc.2013-05-14Not applicableUs
OfloxacinSolution3 mg/mLOphthalmicRemedy Repack2013-11-252016-04-05Us
OfloxacinSolution3 mg/mLOphthalmicRemedy Repack2016-04-112017-02-22Us
OfloxacinSolution / drops3 mg/mLOphthalmicPhysicians Total Care, Inc.2010-04-20Not applicableUs
International/Other Brands
Floxin / Floxstat / Zanocin
Categories
UNII
A4P49JAZ9H
CAS number
82419-36-1
Weight
Average: 361.3675
Monoisotopic: 361.143784348
Chemical Formula
C18H20FN3O4
InChI Key
GSDSWSVVBLHKDQ-UHFFFAOYSA-N
InChI
InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
IUPAC Name
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
CC1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCN(C)CC1

Pharmacology

Indication

For the treatment of infections (respiratory tract, kidney, skin, soft tissue, UTI), urethral and cervical gonorrhoea.

Associated Conditions
Pharmacodynamics

Ofloxacin is a quinolone/fluoroquinolone antibiotic. Ofloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

Mechanism of action

Ofloxacin acts on DNA gyrase and toposiomerase IV, enzymes which, like human topoisomerase, prevents the excessive supercoiling of DNA during replication or transcription. By inhibiting their function, the drug thereby inhibits normal cell division.

TargetActionsOrganism
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
UDNA topoisomerase 2-alpha
inhibitor
Human
Absorption

Bioavailability of ofloxacin in the tablet formulation is approximately 98%

Volume of distribution
Not Available
Protein binding

32%

Metabolism

Hepatic

Route of elimination

Elimination is mainly by renal excretion. Between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via the kidneys within 48 hours of dosing. Four to eight percent of an ofloxacin dose is excreted in the feces. This indicates a small degree of biliary excretion of ofloxacin.

Half life

9 hours

Clearance
Not Available
Toxicity

LD50=5450 mg/kg (orally in mice)

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the neuroexcitatory activities of Ofloxacin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Ofloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Ofloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Ofloxacin.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Ofloxacin.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Ofloxacin.Approved, Experimental, Investigational
AcenocoumarolOfloxacin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Ofloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Ofloxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Ofloxacin.Approved
AlbiglutideOfloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Ofloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Ofloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Ofloxacin.Experimental, Investigational
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Ofloxacin.Experimental
AlogliptinOfloxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AluminiumAluminium can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AmantadineAmantadine may increase the QTc-prolonging activities of Ofloxacin.Approved
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Ofloxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ofloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Ofloxacin.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Ofloxacin.Approved
AnagrelideOfloxacin may increase the QTc-prolonging activities of Anagrelide.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Ofloxacin.Approved, Investigational, Withdrawn
AndrographolideAndrographolide may increase the neuroexcitatory activities of Ofloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Ofloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Ofloxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Ofloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Ofloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
ApocyninApocynin may increase the neuroexcitatory activities of Ofloxacin.Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
Arsenic trioxideOfloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherOfloxacin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineOfloxacin may increase the QTc-prolonging activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Ofloxacin.Investigational
AtazanavirAtazanavir may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Ofloxacin.Approved
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Ofloxacin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Ofloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Ofloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Ofloxacin.Approved, Investigational
BedaquilineOfloxacin may increase the QTc-prolonging activities of Bedaquiline.Approved
BendazacBendazac may increase the neuroexcitatory activities of Ofloxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Ofloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Ofloxacin.Approved
BenzydamineBenzydamine may increase the neuroexcitatory activities of Ofloxacin.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ofloxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Ofloxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Ofloxacin.Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
BromfenacBromfenac may increase the neuroexcitatory activities of Ofloxacin.Approved
BromocriptineOfloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Ofloxacin.Approved
BucillamineBucillamine may increase the neuroexcitatory activities of Ofloxacin.Investigational
BudesonideThe risk or severity of tendinopathy can be increased when Budesonide is combined with Ofloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Ofloxacin.Approved, Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Ofloxacin.Experimental
BuserelinBuserelin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Ofloxacin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Ofloxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium levulinate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinOfloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Ofloxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved, Withdrawn
CaseinCasein can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Ofloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
CeritinibOfloxacin may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Ofloxacin.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Chlorphenamine.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational, Vet Approved
ChlorpropamideOfloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Ofloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Ofloxacin.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Ofloxacin.Approved, Investigational
CisaprideOfloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramOfloxacin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinOfloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Ofloxacin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Ofloxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Ofloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Ofloxacin.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the neuroexcitatory activities of Ofloxacin.Approved
ClorindioneOfloxacin may increase the anticoagulant activities of Clorindione.Experimental
ClozapineClozapine may increase the QTc-prolonging activities of Ofloxacin.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Ofloxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Ofloxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Ofloxacin.Approved, Investigational
CrizotinibOfloxacin may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminCurcumin may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Ofloxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Ofloxacin.Experimental
DabrafenibDabrafenib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ofloxacin.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Ofloxacin.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Ofloxacin.Approved
DelamanidOfloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Ofloxacin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Ofloxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Ofloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Ofloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Ofloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Ofloxacin.Experimental, Vet Approved
DexamethasoneThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Ofloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Ofloxacin.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Ofloxacin.Approved
DiclofenacDiclofenac may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
DicoumarolOfloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Ofloxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Ofloxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Ofloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Ofloxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Ofloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Ofloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Ofloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Ofloxacin.Approved
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Dimenhydrinate.Approved
DiphenadioneOfloxacin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Ofloxacin.Approved, Investigational
DisopyramideOfloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofloxacin.Approved, Investigational
DofetilideOfloxacin may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronDolasetron may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
DomperidoneOfloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Ofloxacin.Approved, Vet Approved
DronedaroneOfloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
DulaglutideOfloxacin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuvelisibDuvelisib may increase the neuroexcitatory activities of Ofloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Ofloxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Ofloxacin.Investigational
EliglustatOfloxacin may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinOfloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Ofloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Ofloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Ofloxacin.Approved
EribulinEribulin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational, Vet Approved
EscitalopramOfloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Ofloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Ofloxacin.Approved
EtanerceptEtanercept may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
EthenzamideEthenzamide may increase the neuroexcitatory activities of Ofloxacin.Experimental
Ethyl biscoumacetateOfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
ExenatideOfloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Ofloxacin.Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Ofloxacin.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Ofloxacin.Approved
FelbinacFelbinac may increase the neuroexcitatory activities of Ofloxacin.Experimental
FenbufenFenbufen may increase the neuroexcitatory activities of Ofloxacin.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ofloxacin is combined with Fenofibric acid.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Ofloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Ofloxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Ofloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric pyrophosphateThe serum concentration of Ofloxacin can be decreased when it is combined with Ferric pyrophosphate.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Ofloxacin.Experimental
FingolimodFingolimod may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
FlecainideOfloxacin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FloctafenineFloctafenine may increase the neuroexcitatory activities of Ofloxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Ofloxacin.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ofloxacin.Approved, Investigational
FluindioneOfloxacin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Ofloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Ofloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Ofloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Ofloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Ofloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Ofloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Ofloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Ofloxacin.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolOfloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Ofloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Ofloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Ofloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Ofloxacin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Ofloxacin.Approved
Fluticasone propionateThe risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Ofloxacin.Approved
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ofloxacin is combined with Fluvastatin.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Ofloxacin.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Ofloxacin.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Ofloxacin.Approved
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Ofloxacin.Approved, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Ofloxacin.Experimental
GliclazideOfloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Ofloxacin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Ofloxacin.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Ofloxacin.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Ofloxacin.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
GuacetisalGuacetisal may increase the neuroexcitatory activities of Ofloxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Ofloxacin.Approved, Investigational, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Ofloxacin.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Ofloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Ofloxacin.Investigational
HistrelinHistrelin may increase the QTc-prolonging activities of Ofloxacin.Approved
HydrocortisoneThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Ofloxacin.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Ofloxacin.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Ofloxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Ofloxacin.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Ofloxacin.Approved, Investigational
IbuprofenIbuprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
IbutilideOfloxacin may increase the QTc-prolonging activities of Ibutilide.Approved
IcatibantIcatibant may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
IloperidoneOfloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Ofloxacin.Experimental
ImipramineImipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Ofloxacin.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Ofloxacin.Approved
IndobufenIndobufen may increase the neuroexcitatory activities of Ofloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
Insulin AspartOfloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirOfloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineOfloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineOfloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanOfloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproOfloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
IronThe serum concentration of Ofloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Ofloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Ofloxacin can be decreased when it is combined with Iron saccharate.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
IsoxicamIsoxicam may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Ofloxacin.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Ofloxacin.Investigational
ItraconazoleItraconazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Ofloxacin.Approved
KebuzoneKebuzone may increase the neuroexcitatory activities of Ofloxacin.Experimental
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
KetoprofenKetoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Ofloxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Ofloxacin.Experimental
Lanthanum carbonateThe serum concentration of Ofloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
LeflunomideLeflunomide may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
LenvatinibOfloxacin may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
LiraglutideOfloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Ofloxacin.Investigational
Lithium cationLithium may increase the QTc-prolonging activities of Ofloxacin.Experimental
LonazolacLonazolac may increase the neuroexcitatory activities of Ofloxacin.Experimental
LopinavirOfloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Loratadine.Approved, Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Ofloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
LumefantrineOfloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Ofloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateMagnesium sulfate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
MasoprocolMasoprocol may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Ofloxacin.Investigational
MecaserminOfloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Ofloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Ofloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Ofloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Ofloxacin.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Ofloxacin.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
MethylprednisoloneThe risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Ofloxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Ofloxacin.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Ofloxacin.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Ofloxacin.Approved
MifepristoneOfloxacin may increase the QTc-prolonging activities of Mifepristone.Approved, Investigational
MiglitolOfloxacin may increase the hypoglycemic activities of Miglitol.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Ofloxacin.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Ofloxacin.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Ofloxacin.Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Ofloxacin.Approved
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Ofloxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Ofloxacin.Approved, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ofloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Ofloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Ofloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Ofloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
NateglinideOfloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Ofloxacin.Investigational
NelfinavirNelfinavir may increase the QTc-prolonging activities of Ofloxacin.Approved
NepafenacNepafenac may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Ofloxacin.Approved, Investigational
NifenazoneNifenazone may increase the neuroexcitatory activities of Ofloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Ofloxacin.Approved
NilotinibOfloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NimesulideNimesulide may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Ofloxacin.Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
OlanzapineOlanzapine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Ofloxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Ofloxacin.Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Ofloxacin.Approved
OlopatadineOlopatadine may increase the neuroexcitatory activities of Ofloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Ofloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Ofloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Ofloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Ofloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Ofloxacin.Approved, Withdrawn
OxytocinOxytocin may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Ofloxacin.Approved, Vet Approved
PaliperidoneOfloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
PalmidrolPalmidrol may increase the neuroexcitatory activities of Ofloxacin.Experimental, Nutraceutical
PanobinostatOfloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Ofloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Ofloxacin.Approved, Investigational
ParthenolideParthenolide may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Ofloxacin.Approved
PazopanibOfloxacin may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Ofloxacin.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Ofloxacin.Experimental
PhenindioneOfloxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Ofloxacin.Approved
PhenprocoumonOfloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Ofloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ofloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
PimozideOfloxacin may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneOfloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Ofloxacin.Experimental
PosaconazolePosaconazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational, Vet Approved
PramlintideOfloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Ofloxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Ofloxacin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Ofloxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Ofloxacin.Approved, Investigational
PrednisoloneThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Ofloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Ofloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Ofloxacin.Approved, Experimental, Investigational
PrimaquinePrimaquine may increase the QTc-prolonging activities of Ofloxacin.Approved
ProbenecidThe serum concentration of Ofloxacin can be increased when it is combined with Probenecid.Approved, Investigational
ProcainamideOfloxacin may increase the QTc-prolonging activities of Procainamide.Approved
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Ofloxacin.Experimental
PromazinePromazine may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Ofloxacin.Approved, Investigational
PropacetamolPropacetamol may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational, Vet Approved
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Ofloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Ofloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Ofloxacin.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
PTC299PTC299 may increase the neuroexcitatory activities of Ofloxacin.Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Quetiapine.Approved
QuinaprilQuinapril can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinidineOfloxacin may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineOfloxacin may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
RepaglinideOfloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Ofloxacin.Approved, Experimental, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Ofloxacin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Ofloxacin.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
RofecoxibRofecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Ofloxacin.Approved, Investigational
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Ofloxacin is combined with Rosuvastatin.Approved
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Ofloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Ofloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ofloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Ofloxacin.Approved
SaquinavirOfloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Ofloxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Ofloxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Ofloxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Ofloxacin.Investigational
SertralineSertraline may increase the QTc-prolonging activities of Ofloxacin.Approved
SevelamerSevelamer can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Ofloxacin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Ofloxacin.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
SotalolOfloxacin may increase the QTc-prolonging activities of Sotalol.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Ofloxacin.Investigational
Strontium ranelateThe serum concentration of Ofloxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Ofloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineOfloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Ofloxacin.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Ofloxacin.Experimental
TamoxifenTamoxifen may increase the QTc-prolonging activities of Ofloxacin.Approved
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Ofloxacin.Investigational
TelavancinOfloxacin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Ofloxacin.Approved
TenidapTenidap may increase the neuroexcitatory activities of Ofloxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Ofloxacin.Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Ofloxacin.Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Ofloxacin.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Terodiline.Experimental
TetrabenazineOfloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Ofloxacin.Approved
ThioridazineOfloxacin may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Ofloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Ofloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Ofloxacin.Investigational
TioclomarolOfloxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Ofloxacin.Approved, Withdrawn
TizanidineTizanidine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
TolazamideOfloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideOfloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
TolmetinTolmetin may increase the neuroexcitatory activities of Ofloxacin.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
ToremifeneOfloxacin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Ofloxacin.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Ofloxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Ofloxacin.Experimental
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
TriptolideTriptolide may increase the neuroexcitatory activities of Ofloxacin.Investigational
TriptorelinTriptorelin may increase the QTc-prolonging activities of Ofloxacin.Approved, Vet Approved
Trolamine salicylateTrolamine salicylate may increase the neuroexcitatory activities of Ofloxacin.Approved
TromethamineTromethamine can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Ofloxacin.Approved
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Ofloxacin.Approved, Investigational
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Valproic Acid.Approved, Investigational
VandetanibOfloxacin may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Ofloxacin.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Ofloxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ofloxacin.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Ofloxacin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Ofloxacin.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Ofloxacin.Approved, Investigational
WarfarinOfloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Ofloxacin.Approved, Investigational, Withdrawn
Zinc acetateZinc acetate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc chlorideZinc chloride can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc oxideZinc oxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZiprasidoneOfloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Ofloxacin.Withdrawn
ZuclopenthixolOfloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid high doses of caffeine.
  • Take without regard to meals.

References

Synthesis Reference
US4382892
General References
Not Available
External Links
Human Metabolome Database
HMDB0015296
KEGG Drug
D00453
KEGG Compound
C07321
PubChem Compound
4583
PubChem Substance
46507574
ChemSpider
4422
BindingDB
50045004
ChEBI
7731
ChEMBL
CHEMBL4
Therapeutic Targets Database
DAP000655
PharmGKB
PA450684
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Ofloxacin
ATC Codes
J01MA01 — OfloxacinS02AA16 — OfloxacinS01AE01 — OfloxacinJ01RA09 — Ofloxacin and ornidazole
AHFS Codes
  • 52:04.04 — Antibacterials
  • 08:12.18 — Quinolones
FDA label
Download (198 KB)
MSDS
Download (73.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1WithdrawnTreatmentHard of Hearing1
2TerminatedTreatmentMinor Intra-uterine Abnormalities1
3CompletedSupportive CareInfection NOS / Multiple Myeloma (MM)1
3CompletedTreatmentAcute Otitis Media1
3CompletedTreatmentConjunctivitis, Bacterial1
3CompletedTreatmentDiabetic Foot Ulcers (DFU)2
3CompletedTreatmentOtitis Media (OM)1
3CompletedTreatmentPelvic Inflammatory Disease (PID)1
3RecruitingTreatmentAcute Male Urinary Tract Infection1
3RecruitingTreatmentKeratitis; Infectious Disease (Manifestation)1
4Active Not RecruitingTreatmentCorneal Transplant / Grafting, Corneal / Keratoplasty, Lamellar / Transplantation, Cornea / Transplantation, Corneal1
4CompletedTreatmentCataracts1
4CompletedTreatmentFevers / Urinary Tract Infections (UTIs)1
4CompletedTreatmentPelvic Inflammatory Disease (PID)1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4Unknown StatusPreventionInfection NOS1
Not AvailableCompletedTreatmentReactive Arthritis1
Not AvailableNot Yet RecruitingTreatmentProsthetic Joint Infection1
Not AvailableRecruitingTreatmentMyopia / Refractive Errors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Akorn Inc.
  • Alcon Laboratories
  • Allergan Inc.
  • American Regent
  • Apotex Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Bausch & Lomb Inc.
  • Cipla Ltd.
  • Daiichi Sankyo
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Doctor Reddys Laboratories Ltd.
  • Falcon Pharmaceuticals Ltd.
  • H.J. Harkins Co. Inc.
  • Hi Tech Pharmacal Co. Inc.
  • Innoviant Pharmacy Inc.
  • Janssen-Ortho Inc.
  • Lake Erie Medical and Surgical Supply
  • Novex Pharma
  • Nucare Pharmaceuticals Inc.
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • Pacific Pharma Lp
  • Pack Pharmaceuticals
  • Par Pharmaceuticals
  • PD-Rx Pharmaceuticals Inc.
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmaforce Inc.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prescript Pharmaceuticals
  • Ranbaxy Laboratories
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Sandhills Packaging Inc.
  • Santen Inc.
  • Teva Pharmaceutical Industries Ltd.
Dosage forms
FormRouteStrength
LiquidIntravenous20 mg
TabletOral200 mg
TabletOral300 mg
TabletOral400 mg
SolutionOphthalmic0.3 %
SolutionAuricular (otic)3 mg/mL
SolutionOphthalmic3 mg/mL
Solution / dropsAuricular (otic)3 mg/mL
Solution / dropsOphthalmic3 mg/mL
Tablet, coatedOral200 mg/1
Tablet, coatedOral300 mg/1
Tablet, coatedOral400 mg/1
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral300 mg/1
Tablet, film coatedOral400 mg/1
Prices
Unit descriptionCostUnit
Floxin Otic 0.3% Solution 10ml Bottle142.91USD bottle
Ofloxacin 10ml Otic (ear) Solution132.19USD bottle
Ofloxacin 10ml. Ophthalmic (eye) Solution87.6USD bottle
Floxin Otic 0.3% Solution 5ml Bottle86.49USD bottle
Ofloxacin 5ml Otic (ear) Solution77.21USD bottle
Ofloxacin 5ml. Ophthalmic (eye) Solution43.86USD bottle
Ocuflox 0.3% eye drops11.35USD ml
Floxin 400 mg tablet9.55USD tablet
Ofloxacin 0.3% eye drops8.08USD ml
Floxin 200 mg tablet6.6USD tablet
Ofloxacin 400 mg tablet6.12USD tablet
Ofloxacin 300 mg tablet5.81USD tablet
Floxin 300 mg tablet5.61USD tablet
Ofloxacin 200 mg tablet4.88USD tablet
Floxin otic singles4.28USD each
Ocuflox 0.3 % Solution2.75USD ml
Apo-Ofloxacin 0.3 % Solution1.04USD ml
Pms-Ofloxacin 0.3 % Solution1.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5401741No1995-03-272012-03-27Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)254 dec °CPhysProp
water solubility28.3 mg/mLNot Available
logP-0.39HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility1.44 mg/mLALOGPS
logP-0.02ALOGPS
logP0.65ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)5.45ChemAxon
pKa (Strongest Basic)6.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area73.32 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity94.94 m3·mol-1ChemAxon
Polarizability36.69 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9545
Blood Brain Barrier-0.9659
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7489
CYP450 2C9 substrateNon-substrate0.8468
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6386
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9268
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7726
Ames testAMES toxic0.7844
CarcinogenicityNon-carcinogens0.9033
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1639 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8402
hERG inhibition (predictor II)Non-inhibitor0.866
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-qTof , NegativeLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-066u-4849000000-62a3272bb7a7b0465316
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-044i-4069000000-fc2f3ccfc4622b82671d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0009000000-8ca4d2a7e1305755f3d3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-02t9-0019000000-a2e5b08b64a9acd1d2f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-1093000000-8403d1bb463eb3fb6e3e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-1090000000-ee50b73ec2b046ce37ca
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ck9-1490000000-8b09e639f03f4aa7a14a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0adl-1950000000-0c369c959a56510a5ff7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-02t9-0029000000-3b84ed4e6dd24267cf5d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-07r0-1590000000-4be12443c6e428a5b6b3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0091000000-a74a0303807ced89f7cc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0cml-0590000000-c08e9fca2077fb0daa17
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0009000000-9046beaae10bda8773cb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0009000000-97824faaceab754612c9
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-0159000000-de443922130ae95667e4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0089-0920000000-16bd425ab62950a6c1f7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-1269000000-01b22da2e2e9a9fdbc27
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03di-2492000000-e0ea454a6ebaa02d7ae9

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Benzoxazines / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines
show 15 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Benzoxazine / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives
show 34 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, organic heterotricyclic compound, N-alkylpiperazine, quinolone antibiotic, fluoroquinolone antibiotic, 3-oxo monocarboxylic acid, oxazinoquinoline (CHEBI:7731)

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Turner AK, Nair S, Wain J: The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets. J Antimicrob Chemother. 2006 Oct;58(4):733-40. Epub 2006 Aug 8. [PubMed:16895934]
  2. Chau TT, Campbell JI, Galindo CM, Van Minh Hoang N, Diep TS, Nga TT, Van Vinh Chau N, Tuan PQ, Page AL, Ochiai RL, Schultsz C, Wain J, Bhutta ZA, Parry CM, Bhattacharya SK, Dutta S, Agtini M, Dong B, Honghui Y, Anh DD, Canh do G, Naheed A, Albert MJ, Phetsouvanh R, Newton PN, Basnyat B, Arjyal A, La TT, Rang NN, Phuong le T, Van Be Bay P, von Seidlein L, Dougan G, Clemens JD, Vinh H, Hien TT, Chinh NT, Acosta CJ, Farrar J, Dolecek C: Antimicrobial drug resistance of Salmonella enterica serovar typhi in asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother. 2007 Dec;51(12):4315-23. Epub 2007 Oct 1. [PubMed:17908946]
  3. Ishiguro F, Toho M, Yamazaki M, Matsuyuki S, Moriya K, Tanaka D, Isobe J, Kyota Y, Muraoka M: [Mutations of gyrA gene and parC gene in fluoroquinolone-resistant Escherichia coli isolates from sporadic diarrheal cases]. Kansenshogaku Zasshi. 2006 Sep;80(5):507-12. [PubMed:17073264]
  4. Drlica K, Zhao X: DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. [PubMed:9293187]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779]
  2. Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V: Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis. 1994 Nov;170(5):1351. [PubMed:7963747]
  3. Shi R, Zhang J, Li C, Kazumi Y, Sugawara I: Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol. 2006 Dec;44(12):4566-8. Epub 2006 Oct 11. [PubMed:17035499]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Divo AA, Sartorelli AC, Patton CL, Bia FJ: Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. [PubMed:2847647]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Terashi K, Oka M, Soda H, Fukuda M, Kawabata S, Nakatomi K, Shiozawa K, Nakamura T, Tsukamoto K, Noguchi Y, Suenaga M, Tei C, Kohno S: Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells. Antimicrob Agents Chemother. 2000 Jun;44(6):1697-700. [PubMed:10817732]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Sasabe H, Tsuji A, Sugiyama Y: Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther. 1998 Mar;284(3):1033-9. [PubMed:9495864]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:49